72 related articles for article (PubMed ID: 16824073)
1. Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C.
Mollison L; Totten L; Flexman J; Beaman M; Batey R
J Gastroenterol Hepatol; 2006 Jul; 21(7):1184-8. PubMed ID: 16824073
[TBL] [Abstract][Full Text] [Related]
2. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.
Gordon A; Hobbs DA; Bowden DS; Bailey MJ; Mitchell J; Francis AJ; Roberts SK
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):275-80. PubMed ID: 16460486
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
Orlent H; Hansen BE; Willems M; Brouwer JT; Huber R; Kullak-Ublick GA; Gerken G; Zeuzem S; Nevens F; Tielemans WC; Zondervan PE; Lagging M; Westin J; Schalm SW
J Hepatol; 2006 Oct; 45(4):539-46. PubMed ID: 16905220
[TBL] [Abstract][Full Text] [Related]
4. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C.
van Rossum TG; Vulto AG; Hop WC; Schalm SW
Am J Gastroenterol; 2001 Aug; 96(8):2432-7. PubMed ID: 11513186
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
6. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection?
Perez RM; Ferreira AS; Medina-Pestana JO; Lanzoni VP; Silva AE; Ferraz ML
Clin Transplant; 2005 Oct; 19(5):622-5. PubMed ID: 16146553
[TBL] [Abstract][Full Text] [Related]
7. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.
McHutchison JG; Patel K; Pockros P; Nyberg L; Pianko S; Yu RZ; Dorr FA; Kwoh TJ
J Hepatol; 2006 Jan; 44(1):88-96. PubMed ID: 16274834
[TBL] [Abstract][Full Text] [Related]
9. Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up.
Hiraga N; Suzuki F; Akuta N; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Matsuda M; Watabiki S; Satoh J; Kumada H
J Med Virol; 2005 Feb; 75(2):240-8. PubMed ID: 15602722
[TBL] [Abstract][Full Text] [Related]
10. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients.
Groenbaek K; Friis H; Hansen M; Ring-Larsen H; Krarup HB
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):985-9. PubMed ID: 16894312
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C infection in Alaska Natives with persistently normal, persistently elevated or fluctuating alanine aminotransferase levels.
Bruce MG; Bruden D; McMahon BJ; Christensen C; Homan C; Sullivan D; Deubner H; Hennessy T; Williams J; Livingston S; Gretch D
Liver Int; 2006 Aug; 26(6):643-9. PubMed ID: 16842319
[TBL] [Abstract][Full Text] [Related]
12. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
Reesink HW; Zeuzem S; Weegink CJ; Forestier N; van Vliet A; van de Wetering de Rooij J; McNair L; Purdy S; Kauffman R; Alam J; Jansen PL
Gastroenterology; 2006 Oct; 131(4):997-1002. PubMed ID: 17030169
[TBL] [Abstract][Full Text] [Related]
13. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.
Veldt BJ; van der Vliet HJ; von Blomberg BM; van Vlierberghe H; Gerken G; Nishi N; Hayashi K; Scheper RJ; de Knegt RJ; van den Eertwegh AJ; Janssen HL; van Nieuwkerk CM
J Hepatol; 2007 Sep; 47(3):356-65. PubMed ID: 17599630
[TBL] [Abstract][Full Text] [Related]
14. Does Silybum marianum play a role in the treatment of chronic hepatitis C?
Torres M; Rodríguez-Serrano F; Rosario DJ; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):69-74. PubMed ID: 16929590
[TBL] [Abstract][Full Text] [Related]
15. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.
Nevens F; Roskams T; Van Vlierberghe H; Horsmans Y; Sprengers D; Elewaut A; Desmet V; Leroux-Roels G; Quinaux E; Depla E; Dincq S; Vander Stichele C; Maertens G; Hulstaert F
Hepatology; 2003 Nov; 38(5):1289-96. PubMed ID: 14578869
[TBL] [Abstract][Full Text] [Related]
17. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.
Sánchez-Conde M; Berenguer J; Miralles P; Alvarez F; Carlos Lopez J; Cosin J; Pilar C; Ramirez M; Gutierrez I; Alvarez E
Clin Infect Dis; 2006 Sep; 43(5):640-4. PubMed ID: 16886160
[TBL] [Abstract][Full Text] [Related]
18. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C.
Hsu CS; Liu CJ; Liu CH; Wang CC; Chen CL; Lai MY; Chen PJ; Kao JH; Chen DS
Liver Int; 2008 Feb; 28(2):271-7. PubMed ID: 18028320
[TBL] [Abstract][Full Text] [Related]
19. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
20. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
